Related Experiment Videos
Physiological signals and oncogenesis mediated through Crk family adapter proteins
1Laboratory of Molecular Oncology, MSZ-Institute for Medical Radiation and Cell Research, University Würzberg, Germany. stephan.feller@mail.uni-wuerzburg.de
Abstract:
The viral Crk oncogene (v-Crk) is known to induce sarcomas in chicken and its cellular homologs c-Crk I, c-Crk II, and Crk-like (CRKL) have been implicated in many signal transduction events. These include cell differentiation, cell migration, and the induced nonresponsiveness of T-cells to stimulation of the T-cell receptor (TCR), a state known as anergy. CRKL is also the most prominent substrate of the Bcr-Abl oncoprotein which causes human chronic myelogenous leukemias (CML). The modular composition of the Crk family adapters which largely consist of Src homology (SH2 and SH3) domains has prompted an intensive search for physiological and pathological upstream and downstream signalling partners which selectively bind to these adapters. Upstream proteins include various receptors and large multisite docking proteins, while several protein kinases and guanine nucleotide release proteins (GNRPs) have been suggested to function downstream of c-Crk and CRKL. Most Crk/CRKL SH2- and SH3-binding proteins contain several docking sites with considerable sequence similarity. Thus the binding requirements of Crk/CRKL SH2 and SH3 domains are now well defined, providing a basis for the design of small inhibitory molecules to block the function of these adapter proteins. The enzymatic cascades activated through Crk family adapters are only partially known, but stress kinases (SAPKs/JNKs) and the GTPase Rap1, as well as the B-Raf isoform of the Raf protein kinases, are affected in some systems. Several yet unidentified, highly selective Crk interacting proteins detectable in specific cell types remain to be studied. More detailed analyses of the enzymatic activities triggered through Crk-type adapters will also be crucial to fully define the signalling pathways controlled by this protein family.
Insights
Crk adapter proteins regulate cell signaling pathways involved in cancer and immunity. Understanding their binding partners and downstream effects is key to developing targeted therapies for diseases like chronic myelogenous leukemia (CML).
Area of Science:
- Molecular Biology
- Oncology
- Signal Transduction
Background:
- The viral Crk oncogene (v-Crk) and its cellular homologs (c-Crk I, c-Crk II, CRKL) are involved in crucial cellular processes like differentiation, migration, and T-cell anergy.
- CRKL is a key substrate of the Bcr-Abl oncoprotein, implicated in human chronic myelogenous leukemias (CML).
- Crk family proteins function as adapter proteins, mediating signal transduction through Src homology (SH2 and SH3) domains.
Purpose of the Study:
- To investigate the upstream and downstream signaling partners of Crk family adapter proteins.
- To define the binding requirements of Crk/CRKL SH2 and SH3 domains for potential therapeutic target identification.
- To elucidate the enzymatic cascades and signaling pathways regulated by Crk-type adapters.
Main Methods:
- Analysis of known and potential protein-protein interactions involving Crk/CRKL SH2 and SH3 domains.
- Identification of upstream signaling proteins (receptors, docking proteins) and downstream effectors (kinases, guanine nucleotide release proteins).
- Review of existing literature on Crk-mediated signaling pathways, including stress kinases (SAPKs/JNKs), Rap1 GTPase, and B-Raf.
Main Results:
- Crk/CRKL binding partners often contain similar docking sites, allowing for well-defined binding requirements for their SH2 and SH3 domains.
- Several upstream and downstream signaling partners have been identified, including kinases and guanine nucleotide release proteins.
- Known downstream pathways affected by Crk adapters include stress kinases (SAPKs/JNKs), Rap1, and B-Raf, though these are only partially understood.
Conclusions:
- The defined binding specificities of Crk/CRKL domains provide a foundation for designing small molecules to inhibit their function.
- Further research is needed to identify novel, highly selective Crk interacting proteins and to fully characterize the enzymatic activities driving Crk-controlled signaling.
- A comprehensive understanding of Crk-mediated signaling pathways is crucial for advancing therapeutic strategies against associated diseases like CML.